Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 36.5 | 62 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 38.0 | 63 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 36.0 | 77 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 34.0 | 80 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 34.0 | 66 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 63.0 | 55 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 61.5 | 60 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 50.0 | 60 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 54.0 | 47 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 63.5 | 64 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 66.0 | 48 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 72.0 | 59 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 72.0 | 61 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 74.5 | 60 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 67.0 | 73 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 82.0 | 60 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 71.0 | 44 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 74.0 | 71 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 86.0 | 62 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 82.5 | 50 | |
N2645 | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 84.0 | 64 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 90.0 | 62 | |
RA2708 | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 82.0 | 51 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 4 | PDGF-BB | 37.0 | 65 | ||||
RA2159 | IKK16 | 2.0 | uM | 4 | PDGF-BB | 32.0 | 68 |